摘要
目的探讨血清ＣｙＦＲＡ２１１和癌胚抗原（ＣＥＡ）对非小细胞肺癌（ＮＳＣＬＣ）的临床价值。方法采用免疫放射分析方法对３０例经临床和病理证实的ＮＳＣＬＣ患者和２０例正常人进行血清ＣｙＦＲＡ２１１和ＣＥＡ联合测定。结果血清ＣｙＦＲＡ２１１值在ＮＳＣＬＣ组的阳性率为４８％，鳞癌组阳性率为６２５％，分别明显高于正常组和腺癌组（Ｐ＜００１）；且与分期有关，Ⅱ期阳性率为３３３％，Ⅲ期为６６７％，Ⅳ期为７２％。血清ＣＥＡ值在ＮＳＣＬＣ组阳性率为４０％，腺癌中阳性率为５０％，分别明显高于正常组和其他类型（Ｐ＜００１）。联合检测ＣｙＦＲＡ２１１和ＣＥＡ可将整个ＮＳＣＬＣ组阳性率提高到６３２％。结论两者联合检测对ＮＳＣＬＣ的诊断、分型、分期和预后判断有一定的临床意义。
PURPOSE To study the clinical significance of serum CyFRA 21 1 and carcinoembryonic antigen (CEA) in non small cell lung cancer (NSCLC). METHODS Serum CyFRA 21 1 and CEA were determined using immunoradiometric assay (IRMA) in 30 NSCLC patients and 20 healthy adults. RESULTS Both the NSCLC group and squamous cell carcinoma(SQC) group with 48% and 62.5% positive CyFRA 21 1 rates respectively were significantly higher than the healthy adults group and adenocarcinoma group. The positive rate of CyFRA 21 1 were also related to the stage of the lung cancer:Stage Ⅱ 33.3% ,Stage Ⅲ 66.7%,Stage Ⅳ 72.2%. The postive rate of CEA in NSCLC group was 40%, in adenocarcinoma group it was 50%, which were significantly higher than healthy adults group and other types group. The postive rate could be elevated to 63.3% in NSCLC group when CyFRA 21 1 and CEA were combined. CONCLUSIONS CyFRA 21 1 combined with CEA seemed to have clinical value in the diagnosis, classification, staging and prognosis of NSCLC.
出处
《中国癌症杂志》
CAS
CSCD
1997年第4期273-274,共2页
China Oncology
关键词
非小细胞
肺癌
细胞角蛋白
癌胚抗原
诊断
预后
carcinoma,non small cell lung
cytokeratin
carcinoembryonic antigen
